Endoscopic ultrasound-guided ethanol and radiofrequency ablation of pancreatic insulinomas: a systematic literature review

Ghassan El Sayed, Levente Frim, Jamie Franklin, Raymond McCrudden, Charles Gordon, SaFa Al-Shamma, Szabolcs Kiss, Péter Hegyi, Bálint Erőss1 and Péter Jenő Hegyi

Abstract

Background: Insulinoma is the most common neuroendocrine neoplasm of the pancreas, characterised by hypoglycaemic symptoms. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and ethanol ablation (EUS-EA) are novel methods for treating insulinoma. We aimed to perform a systematic review to assess the efficacy and safety of EUS-guided ablation techniques for pancreatic insulinomas.

Methods: We systematically searched for articles detailing EUS-guided ablations of insulinomas. We performed a qualitative analysis and summarised data on the efficacy and safety of EUS-RFA and EUS-EA techniques.

Results: In total, we identified 35 case reports and case series describing 75 patients with insulinomas treatment with EUS-guided ablation. Twenty-seven patients were treated with EUS-RFA, 47 patients with EUS-EA, and 1 patient received EUS-EA and EUS-RFA in the same session. In total, 84 insulinomas were ablated (EUS-RFA: 31, EUS-EA: 53). Most insulinomas were in the head of the pancreas (40%). The clinical success rate for EUS-guided ablation techniques was 98.5%. The median glucose level was 1.95 (Q1–Q3: 1.69–2.13) mmol/L before ablation compared to 6.20 (Q1–Q3: 5.30–7.05) mmol/L after treatment. The median insulin and C-peptide levels before and after RFA/EA were 230 (Q1–Q2: 120–257) pmol/L and 41 (Q1–Q2 35–42) pmol/L; 2077 (Q1–Q2 1644–2459) pmol/L and 819 (Q1–Q2 696–1072) pmol/L, respectively. There were eleven adverse events: seven abdominal pain, two mild acute pancreatitis, one necrotising acute pancreatitis and one local hematoma. All patients recovered, and there were no periprocedural deaths.

Conclusions: EUS-guided ablation of insulinoma seems to be a safe and effective treatment and is an alternative to surgical resection in selected cases.

Keywords: endoscopic ultrasound, endoscopic ultrasound-guided ethanol ablation, endoscopic ultrasound-guided radiofrequency ablation, insulinoma

Received: 16 April 2021; revised manuscript accepted: 15 July 2021.

Introduction

Insulinomas are a rare type of pancreatic neuroendocrine tumours (pNET) that autonomously secrete insulin,1 which can cause to inappropriate hypoglycaemic episodes during fasting, typically in the morning.2 In addition, sympathetic activation and catecholamine secretion can lead to excessive perspiration, tachycardia, palpitation, generalised weakness, and food craving.3,4 Typically, all these symptoms promptly disappear following either oral or IV glucose administration.5 Insulinomas are rare tumours;
the prevalence of functioning insulinomas is estimated to be between one and four per million persons in the general population. Most insulinomas are within the pancreas, where the majority (90%) are located in the pancreatic head and body, and the majority are benign.

Surgical resection is still the gold standard treatment for insulinomas. Even using minimally invasive laparoscopic techniques (i.e. surgical enucleation), complications such as pancreatic fistulas and sepsis can occur. Alternatively, non-surgical treatments such as high-carb foods, including night-time snacks, combined with medical therapy (e.g. diazoxide, somatostatin analogues or octreotide), which can control symptoms in some patients.

Image-guided ablative techniques are widely used as an alternative to major surgery for treating tumours in the lung, liver and kidney. The pancreas is readily accessible during EUS, and an EUS-guided ablation is, therefore, an option for delivering ablative treatments. EUS-guided ablation was first reported in 2006, and there is a growing body of evidence on its safety and efficacy. These techniques have created new treatment pathways, especially for elderly or frail patients with multiple comorbidities where there are higher risks associated with major surgery. There are two main techniques used, EUS-guided radiofrequency ablation (EUS-RFA) and EUS-guided ethanol ablation (EUS-EA). The concept behind RFA is to produce thermal energy within the tumour, which induces tissue necrosis by cell protein denaturation. Ethanol is also an effective cheap, and rapid-acting ablative agent. It has successfully stimulated tissue necrosis in various organs, e.g. thyroid gland, spleen, kidney and liver, with minimal side effects recorded.

Previous studies showed that EUS-guided injection of alcohol was successfully performed to treat liver metastases, gastrointestinal stromal tumours (GISTs) and pancreatic cysts. Our systematic review aimed to perform a descriptive analysis of EUS ablation techniques with RFA and EA in insulinoma patients.

Material and methods
This study is reported following the Preferred Reporting Items for Systematic Review (PRISMA) Statement. The protocol of the systematic review was registered in PROSPERO under the registration number CRD 42021234378.

Search
We conducted a systematic search (GES, LF) in six databases, including MEDLINE (via PubMed), EMBASE, Cochrane Controlled Register of Trials (CENTRAL), Web of Science, Scopus, and ClinicalTrials.gov. with the query (endoscopic ultrasound AND (insulinoma)). We searched all relevant reports from inception to 24/11/2020 without restrictions.

Selection, screening and data collection
Duplicates were removed using EndNote X7.4 (Clarivate Analytics, Philadelphia, PA, USA), then two independent review authors (GES, LF) screened all relevant titles, abstracts, and full-text publications against the eligibility criteria. Disagreements were resolved by consensus.

Eligibility criteria
We included all records on adults (>18 years) with insulinomas treated by EUS-guided RFA/EA. Regarding the study design, we narrowed the focus to case-control, case series studies and prospective and retrospective cohort studies (regardless of the publication type, i.e. conference abstract or full-text format). There was no language restriction. We excluded all articles where EUS-RFA or EUS–EA was carried out intraoperatively or used another type of EUS-guided ablation technique. All study designs were eligible, but we excluded reviews. If there were multiple publications on the same cohorts of patients, the larger and more recent study population was included.

Data extraction
All data were independently extracted by two co-authors (GES, LF) from relevant studies and added to a pre-defined Excel datasheet (Office 365, Microsoft, Redmond, WA, USA). The following data were extracted: study settings (study population, number of patients with insulinoma, indication for EUS-guided RFA/EA, geographical region, recruitment period, the total number of treated insulinoma, number of treatment sessions and passes, type of needle used in EUS-guided...
RFA/EA (Gr), median ethanol concentration in EA (%), the median time duration in RFA/EA (s), median energy setting (Watt), in RFA, and essential characteristics of the study population (age, gender, comorbidities, BMI, and laboratory parameters (glucose-, insulin-, and C-peptide levels), diagnostic criteria of insulinoma and EUS-guided ablation techniques. The patients’ data were retrospectively analysed.

Quality assessment
Two co-authors (GES, LF) used Murad et al.\textsuperscript{20} tool to assess case studies and case series to evaluate the included studies’ quality. This tool covered four main domains, including selection, ascertainment, causality, and reporting. We did not aggregate scores but discussed these findings as limitations of the evidence as per Murad et al.\textsuperscript{20} recommendations.

Results

Search and selection
A total of 1444 records were identified in 6 databases. Out of the 102 publications screened by full text, we excluded 67 papers. The flow chart of the selection is detailed in Figure 1. The most common causes of exclusion on full-text assessment were lack of relevant data, overlapping case reports and case series, and the use of different
EUS-ablation techniques. Finally, 35 non-overlapping case reports and case series were identified and included in the qualitative analysis. Eleven articles reported EUS-RFA and 23 articles EUS-EA technique, and 1 case report reported using both techniques.\(^{10,16,21–52}\)

**Characteristics of the studies included**

We performed a descriptive analysis of all published EUS-guided RFA/EA of insulinomas. We used boxplots for all laboratory parameters pre- and post-EUS-guided RFA/EA techniques within the descriptive analysis. The included studies’ main characteristics are summarised in Tables 1–5. One article was in Hungarian.\(^{23}\) The 34 remaining articles were written in English.\(^{10,16,21–24,26–52}\) Fifteen reports were from Europe,\(^{10,22–24,26–30,34,40,45,49–51}\) nine from Asia,\(^{25,32,33,35,37,41–43,53}\) eight from the United States of America,\(^{16,31,36,39,44,47,48,52}\) two from South America,\(^{38,46}\) and one from Egypt.\(^{21}\) Our comprehensive search did not identify any comparative studies (controlled); all data emerged from descriptive studies (case reports or case series).

**Quality assessment**

The quality of the studies included is summarised in Supplementary Table 1.

**Findings of the systematic review**

**Main epidemiology characteristics in studies included.** Altogether we analysed 55 articles in our systematic review. Eleven studies reported on EUS-guided RFA,\(^{22,25,28,30–32,34,40,44,50}\) twenty-three on EUS-guided EA,\(^{10,16,21,23,24,26,27,29,35–39,41–43,45–49,51,52}\) and one on both techniques.\(^{33}\) The total number of patients was seventy-five, of whom 26 were male, 38 female and 11 patients’ gender was not reported.\(^{30}\) The male: female ratio in our study was 42:58%, respectively. The average age of all patients was 55 ± 19.91 years, of which the average male and female age were 51 ± 20.21 and 58 ± 19.36 years, respectively. For the detailed demographic characteristics, see Tables 6–8.

**Main characteristics of RFA treated group.** The EUS-RFA group included 27 patients; 11 patients had no gender and age reported.\(^{30}\) The male and female ratio in this group was seven versus nine, respectively. The average age was 52 ± 14.63 and 52 ± 16.61 years, in males and females, respectively (Tables 6, 7).

**Main characteristics of EA treated group.** The EUS-EA group included 47 patients (male:19; female:28). The average age of male versus female was 50 ± 22.58 vs 60 ± 19.99 years, respectively (Tables 6, 7).

**Main characteristics of insulinomas, ablation techniques, and location.** Eighty-four insulinomas were ablated across all included patients (EUS-RFA: 31 insulinomas vs EA: 53 insulinomas). One patient received both EUS-guided EA and EA in the same session.\(^{33}\) Six patients had multiple insulinomas:\(^{33,35,38,40,42,47}\) two patients had three insulinomas located in the head, body and tail;\(^{35,42}\) one patient in the head and body;\(^{46}\) two patients in the body and tail of the pancreas;\(^{38,47}\) one patient in the head and uncinate process of the pancreas.\(^{40}\) All patients treated by RFA had solitary insulinoma. Sixty-five insulinomas were ablated in 47 patients by EA.

**Insulinoma location and size.** Thirty-two (40%) of the insulinomas were located in the head of the pancreas, 18 (22%) in the body, 12 (15%) in the tail, 8 (10%) in the uncinate process, 5 (6%) in the neck, 3 (4%) in the body/tail area, 2 (2%) in the head/body area and four insulinomas were unreported (Figure 2). The pre-treatment (EUS-guided ablation) median size of all insulinomas was 13 mm x 10 mm (range: 4–27 mm x 2–27 mm). The post-treatment median size of insulinomas was 3x5 mm (range: 3–7 mm x 5–7 mm).

**Indications of EUS-guided ablation.** Twenty-one (32%) of patients had multiple co-morbidities precluding general anaesthesia and abdominal surgery (coronary heart diseases, arterial hypertension, cardiac valve replacement, severe aortic stenosis, cardio-vascular diseases, advanced kidney disease, morbid obesity, COPD, sleep apnoea and advanced age). Twenty-one (32%) refused surgery, and 3 (5%) had anatomically unfavourable insulinoma locations for surgical resection. Incomplete resections before EUS-guided ablation were identified in one patient. Surgical resection after EUS-guided ablation was noted in one of the cases. Five studies did not explain the indication (Figure 3).

**Descriptive analysis of EUS-guided EA.** In total, 47 patients underwent EUS-guided EA (19 male, 28
**Table 1.** Main characteristics of the studies included. Patients treated with EUS-guided RFA technique. NA: not applicable, F: female, M: male, RFA: radifrequency ablation, p.: patient, EUS: endoscopic ultrasound.

| Study population | Country  | No. of patients with insulinoma | Gender (M:F) | Age (y) | Indication for EUS-RFA | No of insulinomas | No of sessions | No of passes | Watts | RFA duration (s) | Glucose (mmol/L) | Insulin (pmol/L) | C-peptid (pmol/L) | Type of adverse event |
|------------------|---------|--------------------------------|--------------|---------|------------------------|------------------|----------------|--------------|-------|-----------------|-----------------|------------------|------------------|-------------------|
| Bas-Cutrina et al.22 | Spain | 1 | F 63 | comorbidity | 1 | 1 | 3 | 10 | 360 | NA | NA | NA | NA | NA | NA | no |
| Choi et al.23 | Korea | 1 | M 34 | refuse and high surgical risk | 1 | 1 | 3 | 50 | 10 | NA | NA | NA | NA | NA | NA | no |
| De Nucci et al.24 | Italy | 1 | F 76 | comorbidity | 1 | 1 | 2 | 10 | 60 | 1.9 | NA | NA | NA | NA | NA | no |
| Godat et al.25 | Switzerland | 1 | NA NA | NA | 1 | 1 | 3 | 50 | 10 | NA | NA | NA | NA | NA | NA | no |
| Jonica and Wagh26 | USA | 1 | F 57 | comorbidity | 1 | 1 | 5 | 30 | 20 | 2.22 | 7.66 | 257 | NA | NA | NA | no |
| Kandula et al.27 | India | 1 | F 41 | refuse surgery | 2 | NA | NA | NA | NA | 2.22 | NA | NA | NA | NA | NA | abd. pain, acute pancreatitis |
| Kluz et al.28 | Poland | 1 | M 40 | refuse surgery | 1 | 3 | NA | 50 | 10 | NA | NA | NA | NA | NA | NA | acute necro. pancreatitis |
| Oleinikov et al.29 | Israel | 7 | M 44 | refuse surgery | 1 | 1 | NA | 10-50 | 5-12 | 3.38 ± 0.34 | 6.61 ± 0.13 | NA | NA | NA | NA | no |
| Sharma et al.30 | USA | 2 | M 44 | refuse surgery | 1 | 3 | NA | 10 | NA | 1.72 | NA | NA | NA | NA | NA | NA |
| Waung et al.31 | UK | 1 | F 70 | comorbidity | 1 | 3 | 3 | 10 | NA | 1.6 | NA | 120 | NA | 2418 | NA | NA |
| Lakhtakia et al.32 | India | 10 | NA NA | NA | 13 | 8 p./1 2 p./>1 | NA | NA | NA | normal | NA | normal | normal | normal | Abd.pain, acute panc. |
Table 2. Main characteristics of the studies included. Patients treated with EUS-guided EA technique. NA: not applicable, F: female, M: male, EA: ethanol ablation, EUS: endoscopic ultrasound.

| Study population          | Country   | No. of patients with insulinoma | Gender (M/F) | Age (years) | Indication for EUS-EA | No of insulinomas | No of sessions | No of passes | Ethanol concentration (%) | Ethanol volume (ml) | Glucose (mmol/L) | Insulin (pmol/L) | C-peptid (pmol/L) | Type of adverse event |
|--------------------------|-----------|---------------------------------|--------------|-------------|------------------------|-------------------|----------------|-------------|--------------------------|-------------------|-----------------|------------------|------------------|---------------------|
| Altonbary et al.         | Egypt     | 1                               | M            | 35          | refuse surgery         | 1                 | 2              | 2           | NA                       | 6                 | 1.67            | NA                | NA               | no                  |
| Bor et al.               | Hungary   | 1                               | F            | 83          | comorbidity            | 1                 | 1              | 2           | 96                       | 3                 | 1.7             | 3.5              | 185              | NA                  |
| Burghardt et al.         | Germany   | 1                               | F            | 65          | comorbidity            | 1                 | 1              | NA          | 96                       | 1                 | 2.1             | 7.5              | 271              | NA                  |
| Dabkowski et al.         | Poland    | 1                               | F            | 81          | comorbidity            | 1                 | 2              | NA          | 96                       | 3                 | 1.61            | 4.61             | 231              | 34                  |
| Sousa et al.             | Portugal  | 1                               | F            | 89          | comorbidity            | 1                 | 1              | NA          | 95                       | 0.6               | 2.11            | NA               | 83.3             | NA                  |
| Deprez et al.            | Belgium   | 1                               | F            | 78          | comorbidity            | 1                 | NA             | NA          | 98                       | 3.5               | 1.9             | 6.2              | 229.6            | 43.1                |
| Jürgenssen et al.        | Germany   | 1                               | F            | 78          | refuse surgery         | 1                 | 1              | 4           | 95                       | 8                 | 0.8             | 5.3              | 560              | 41                  |
| Lee et al.               | Korea     | 1                               | F            | 26          | tumour location (multiple ins.) | 4                 | 1              | 3           | 95                       | 3.2               | 2               | 5.3              | 106.3            | 61.8                |
| Levy et al.              | USA       | 5                               | F            | 72          | comorbidity            | 1                 | 2              | 5           | 98                       | 0.37              | NA              | 7.77             | NA               | NA                  |
|                          |           |                                 | M            | 82          | comorbidity            | 1                 | 3              | 7           | 95                       | 0.62              | NA              | NA               | NA               | NA                  |
|                          |           |                                 | F            | 80          | comorbidity            | 1                 | 2              | 9           | 98                       | 1.23              | NA              | NA               | NA               | NA                  |
|                          |           |                                 | F            | 57          | refuse surgery         | 1                 | 2              | 7           | 98                       | 4.5               | NA              | NA               | NA               | NA                  |
|                          |           |                                 | M            | 34          | refuse surgery         | 1                 | 2              | 9           | 99                       | 1.7               | NA              | NA               | NA               | NA                  |
Table 3. Main characteristics of the studies included. Patients treated with EUS-guided EA technique. NA: not applicable, EA: etanol ablation, EUS: endoscopic ultrasound.

| Study population | Country | No. of patients with insulinoma | Gender (M/F) | Age (y) | Indication for EUS-EA | No of insulinomas | No of sessions | No of passes | Ethanol concentration (%) | Ethanol volume (ml) | Glucose (mmol/L) | Insulin (pmol/L) | C-peptid (pmol/L) | Type of adverse event before EA | Type of adverse event after EA |
|------------------|--------|--------------------------------|--------------|---------|------------------------|------------------|----------------|-------------|--------------------------|-------------------|-----------------|----------------|----------------|----------------|----------------|-----------------|
| Luo et al.       | China  | 1                              | M            | 32      | comorbidity            | 1                | 1              | NA          | 99                       | 1.5               | NA              | NA              | NA             | NA             | NA              | no              |
| Mittal et al.    | USA    | 1                              | M            | 59      | unresectable           | 1                | 2              | 2           | NA                       | 2.8               | NA              | NA              | NA             | NA             | NA              | no              |
| Mosquera-Klinger et al. | Colombia | 2 | F | 40 | refuse surgery | 1 | 1 | 2 | 96 | 2 | 2 | NA | NA | NA | NA | NA | no |
|                  |        | F                              | 80           |         | comorbidity            | 1                | 1              | 2           | 96                       | 2                 | NA              | NA              | NA             | NA             | NA              | no              |
| Nelson et al.    | USA    | 1                              | F            | 81      | comorbidity            | 1                | 1              | NA          | 98                       | 1                 | NA              | NA              | NA             | NA             | NA              | no              |
| Paik et al.      | Korea  | 3                              | M            | 99      | refuse surgery         | 1                | 1              | NA          | NA                       | 1.2               | NA              | NA              | NA             | NA             | NA              | no              |
|                  |        | M                              | 20           |         | refuse surgery         | 1                | 1              | NA          | 2.5                      |                   |                 |                 |                 |                 |                 |                 |
|                  |        | M                              | 32           |         | refuse surgery         | 1                | 1              | NA          | 3                       |                   |                 |                 |                 |                 | abd.pain        |                 |
| Park et al.      | Korea  | 2                              | F            | 66      | refuse surgery         | 1                | 2              | 2           | 99                       | 6.4               | NA              | NA              | NA             | NA             | NA              | no              |
|                  |        | F                              | 27           |         | comorbidity            | 3                | 1              | 3           | 99                       | 3.2               | NA              | NA              | NA             | NA             | NA              | no              |
| Study | Country | population | No. of patients | No. of insulinomas | No of sessions | No of passes | Ethanol concentration (%) | Ethanol volume (ml) | Glucose (mmol/L) | Insulin (pmol/L) | C-peptid (pmol/L) | Type of adverse event before EA | Type of adverse event after EA |
|-------|---------|------------|----------------|-------------------|--------------|-------------|--------------------------|-------------------|----------------|----------------|----------------|---------------------------------|-----------------------------|
| Qin et al. | China 17 | F 48 | 1 | 1 | NA | 0.5 | NA | NA | NA | NA | NA | AMS level increase | no |
|         |         | F 56 | 1 | 1 | 3 | 0.35 | no | no | no | no | no | no |
|         |         | M 56 | 1 | 1 | 0.5 | no | no | no | no | no | no | no |
|         |         | M 56 | 1 | 2 | 2 | 0.3 | no | no | no | no | no | no |
|         |         | F 46 | 1 | 1 | 1 | 0.3 | no | no | no | no | no | no |
|         |         | M 66 | 1 | 1 | 1 | 0.5 | no | no | no | no | no | no |
|         |         | M 46 | 1 | 1 | 2 | 2 | no | no | no | no | no | no |
|         |         | M 46 | 1 | 1 | 2 | 2 | no | no | no | no | no | no |
|         |         | M 66 | 1 | 1 | 1 | 0.5 | no | no | no | no | no | no |
|         |         | M 33 | 1 | 1 | 1 | 0 | no | no | no | no | no | no |
|         |         | M 24 | 1 | 1 | 3 | 1.3 | no | no | no | no | no | no |
|         |         | F 56 | 1 | 1 | 1 | 0.5 | no | no | no | no | no | no |
|         |         | F 56 | 1 | 1 | 1 | 0.3 | no | no | no | no | no | no |
|         |         | F 42 | 1 | 1 | 3 | 1.3 | no | no | no | no | no | no |
|         |         | F 42 | 1 | 1 | 1 | 0.5 | no | no | no | no | no | no |
|         |         | M 24 | 1 | 1 | 3 | 1.3 | no | no | no | no | no | no |
|         |         | M 28 | 1 | 1 | 1 | 0.5 | no | no | no | no | no | no |
|         |         | F 51 | 1 | 1 | 3 | 2.9 | no | no | no | no | no | no |
|         |         | F 51 | 1 | 1 | 1 | 1.2 | no | no | no | no | no | no |
|         |         | F 42 | 1 | 1 | 1 | 1 | no | no | no | no | no | no |
|         |         | F 42 | 1 | 1 | 1 | 1 | no | no | no | no | no | no |
|         |         | F 42 | 1 | 1 | 1 | 1 | no | no | no | no | no | no |
|         |         | M 35 | 1 | 1 | 1 | 1 | no | no | no | no | no | no |
|         |         | F 42 | 1 | 1 | 1 | 1 | no | no | no | no | no | no |
|         |         | F 42 | 1 | 1 | 1 | 1 | no | no | no | no | no | no |
Table 5. Main characteristics of the studies included. Patients treated with EUS-guided EA technique. NA: not applicable.

| Study population | Country          | No. | Gender | Age (y) | Indication for EUS-EA | No of insulominas | No of sessions | No of passes | Ethanol concentration (%) | Ethanol volume (ml) | No of insulinomas | No of sessions | No of passes | Ethanol concentration (%) | Ethanol volume (ml) | Glucose (mmol/L) | Insulin (pmol/L) | C-peptid (pmol/L) | Type of adverse event |
|------------------|-----------------|-----|--------|---------|-----------------------|------------------|----------------|------------|--------------------------|-------------------|-------------------|---------------|-------------|--------------------------|-------------------|----------------|----------------|----------------|---------------------|
| Schnack et al.55  | Denmark         | 1   | M      | 89      | comorbidity           | 1                | NA            | NA         | 98                        | 3.5               | NA                | NA            | NA          | NA                       | NA                | NA             | NA             | NA             | mild AP             |
| Silva et al.66    | Brazil          | 1   | F      | 21      | comorbidity           | 1                | NA            | NA         | 99                        | 1.5               | NA                | NA            | NA          | NA                       | NA                | NA             | NA             | NA             | no                  |
| Trevino et al.67  | USA             | 1   | F      | 79      | tumour location       | 2                | 1             | 2          | 98                        | 12                | NA                | NA            | NA          | NA                       | NA                | NA             | NA             | NA             | no                  |
| Trikudantha et al.58 | USA             | 1   | F      | 66      | comorbidity           | 1                | 1             | 4          | NA                        | 2.5               | NA                | 228           | NA          | 2473                      | NA                | NA             | NA             | no             | no                  |
| Vleggar et al.59  | The Netherlands | 1   | F      | 82      | comorbidity           | 1                | NA            | NA         | 96                        | 0.3               | 2.2               | 6.4           | 97.2        | 41.7                      | 1820              | 910            | no             | no             | no                  |
| Zalewska et al.51 | Poland          | 1   | F      | 72      | comorbidity           | 1                | 2             | NA         | 96                        | 2                 | 1.8               | NA            | 1.8         | NA                       | NA                | NA             | NA             | NA             | abd.pain            |
| Zarug et al.52    | USA             | 1   | M      | 56      | comorbidity           | 1                | NA            | NA         | NA                        | 1.5               | 2.05              | NA            | 252         | NA                       | NA                | NA             | NA             | no             | no                  |
Table 6. Basic characteristics across groups.

| Gender | Total mean age |  |  |  |  |  |  |  |
|--------|----------------|---|---|---|---|---|---|
|        | Age            |  |  |  |  |  |  |
|        | mean (y)       | SD | Range | mean (y) | SD | Range |
| Male   | 26             | 51 | ±20.21 | 20–99 | 55 | ±19.91 | 20–99 |
| Female | 38             | 58 | ±19.36 | 21–89 |
| N/A    | 11             |  |  |  |  |  |
| Total  | 75             |  |  |  |  |  |
|        |  |  |  |  |  |  |
|        | mean (y)       | SD | Range |
|        | 55             | ±19.91 | 20–99 |

Table 7. Age (y) distribution across EUS-guided radiofrequency and ethanol ablation groups.

| AGE-EA      | AGE-RFA      | Total age RFA | Total age EA |
|-------------|--------------|---------------|--------------|
| MALE        | FEMALE       | MALE          | FEMALE       |
| Mean        | 49.73        | 60.21         | 51.57        | 51.66        |
| Min         | 20           | 21            | 34           | 28           |
| Max         | 99           | 89            | 73           | 76           |
| SD          | ±22.58       | ±19.99        | ±14.63       | ±16.61       |

Table 8. Main characteristics of included articles.

| Number of included articles | EUS-RFA: number of patients | EUS-EA: number of patients |
|-----------------------------|-----------------------------|---------------------------|
| EUS-RFA                     | 11                          | MALE                      | FEMALE        |
| EUS-EA                      | 23                          | 7                         | 9             |
| RFA + EA                    | 1                           | TOTAL: 16                 | TOTAL: 47     |
| TOTAL                       | 35                          | 11 patient: unknown gender|

female) with a median alcohol concentration of 98%, of whom 25 patients received one session (average volume injected 1.58 mL), 13 patients had two sessions (average volume 1.24 mL), four patients had three sessions (average volume 1 mL), and five patients had an unclear number of sessions and volume reported (Tables 9, 10). Volumes injected per session ranged from 0.3 mL to 6 mL (median volume 1.55 mL). The median number of sessions and passes were one and two, respectively. In all, 25-gauge needles were used for 4 patients, 22-gauge for 18 patients, and 19-gauge needles for two patients. The type of needle was not recorded in the other remaining cases.

Descriptive analysis of EUS-guided RFA. Ten patients (4 male/5 female and one unknown gender) underwent EUS-RFA with a median energy setting at 10 Watts (range: 10–50 W) and a median ablation duration of 15 seconds. The energy setting was not recorded in the remaining cases. Twelve patients received one session, four patients had three sessions, and one patient had an unknown number of sessions. The median number of
sessions and passes were 2 and 3, respectively (Table 1). In all, 19-gauge needles were used in 8 patients, and 18-gauge and 22-gauge in one patient each.\textsuperscript{22,33} (Tables 9, 10).

**Laboratory parameters findings.** Pre-ablation EUS-guided RFA and EA biochemical parameters revealed (average serum glucose- \((\text{data from 20 patients})\), insulin (13 patients), and C-peptide (10 patients) levels; 1.95 (Q1–Q3 1.69–2.13) mmol/L; 230 (Q1–Q3 120–257) pmol/L; 2077 (Q1–Q3 1644–2459) pmol/L, respectively). Post-ablation EUS-guided RFA and EA biochemical results showed 6.20 (Q1–Q3 5.30–7.05) mmol/L (11 patients); 41 (Q1–Q3 35–42) pmol/L (six patients); 819 (Q1–Q3 696–1072) pmol/L (four patients), respectively (Figure 4(a), (b), (c)).

**Follow-up period of post-EUS ablation techniques and follow-up imaging techniques.** Fifteen out of the 35 reviewed articles reported the imaging modality that was used for post-EUS ablation follow-up. Transabdominal US, MRI, and PET-CT follow-up were each reported in one article; seven reported the use of CT, and five articles reported the use of EUS. All these imaging techniques showed significant reduction or complete resolution of pancreatic insulinomas in the post-ablation follow-up period. Twenty-eight articles of 35 inconsistently reported the duration of the follow-up period. The average follow-up period post-ablation was 9 months (range: 5–1460 days).

**Adverse events.** Eleven out of 75 (15%) patients had complications following EUS-guided ablation,
five (18%) after EUS-RFA and six (13%) after EUS-EA. All five patients in the EUS-RFA group had experienced abdominal pain, two of them developing mild acute pancreatitis, and one had severe necrotising pancreatitis. In the case of EUS-guided EA, three patients complained of abdominal pain; one had duodenal perforation with bleeding. Technical and clinical success rates were 98.5% for both modalities, and no deaths occurred. One patient, following the failure of EUS-EA, needed surgical resection.

Body composition. Body mass index was only reported in six cases. In 5 female and 1 male patient, the average age was 55 (range: 21–78) years. Obesity (BMI > 40 kg/m²) was recorded in four cases.

Discussion

Efficacy of ablation techniques

Animal models have previously demonstrated the safety and efficacy of EUS-RFA and EUS-EA techniques. These results had prompted the use of these ablation techniques in different human conditions. The published literature suggests that EUS-guided ablation techniques (RFA/EA) for insulinoma have a high technical success rate (64 out of 65; 98.5%); equally the clinical success rate was promising in this cohort of patients, as only 1 patient out of 65 patients required further surgical management. In our systematic review, the clinical success was measured with the normalisation of biochemical parameters, including serum glucose levels, C-peptide levels and insulin levels. The radiological response was also appreciated during the follow-up period, as most of these patients had complete resolution of their insulinomas after EUS-guided ablation (RFA/EA).

In comparison, the French prospective multicentre study of Barthet et al. demonstrated 86% efficacy with the EUS-RFA technique of 14 solid pancreatic neuroendocrine tumours after 1-year follow-up and complete resolution of three insulinomas after a 2-year follow-up. Jürgensen et al. reported the first case of EUS–EA of a 13 mm pancreatic insulinoma in 2006. Our review highlighted that multiple insulinomas were also described in our literature search that ethanol ablation was performed with excellent clinical outcome. Regardless of the number of insulinomas, EUS-EA proved to be effective and spared surgical intervention.

The first successful treatment of multiple insulinomas with EUS-EA in a multimorbid patient from the United States was published in 2011. It immediately improved the blood glucose levels;
the treatment response was sustained at 4 months follow-up when no hypoglycaemic episodes occurred. Both ablation techniques can be safely applied in the same patient with multiple insulinomas; this was demonstrated by Khoo et al., where a patient had recurrent insulinoma following distal pancreatectomy. The insulinoma in the head was ablated with EUS-EA and the insulinoma in the body with EUS-RFA.

Ablation techniques. Based on our systematic review, the median volume and median alcohol concentration were used (1.55 mL and 98%, respectively), but due to the lack of data, we could not describe the exact volume of alcohol injected in each insulinoma depending on its distribution within the pancreatic gland. This finding can help to design a detailed protocol for this technique. There are no established guidelines on the volume of highly concentrated ethanol, the number of injections per session, the ideal tumour size, and the needle size.

EUS-guided ablation techniques have been trialled for different indications using variable techniques. Burghardt et al. published the results of a multicentre, randomised, double-blind study comparing EUS-guided 80% ethanol lavage versus saline injection for cystic pancreatic lesions. They demonstrated that the ethanol group had a more significant decrease in the size of cystic pancreatic benign lesions than saline solution injection. EUS-guided alcohol injection is an established method of ablat ing the coeliac plexus (neurolysis) to achieve pain control; this is usually done with the same needle as FNA. We described that the alcohol could be delivered using variable needle sizes (19-gauge, 22-gauge and 25-gauge needle), and it does not influence its technical and clinical success. On the other hand, our data showed that the standard EUS-RFA probe needle used was a 19-gauge needle which allowed easy access to the lesions and successful ablations. Interestingly, the median energy setting of EUS-RFA was 10 Watt (range: 10–50 Watt). This is probably due to all cases reported had almost similar lesion size (median size: 13 mm x 10 mm).

EUS-guided RFA was first described in a porcine model. Goldberg et al. in the year 1999 studied the effect of RFA on normal pancreatic tissue on Yorkshire pigs. His work included histological examination of the ablated healthy pancreatic tissues in his pig model, and this was carried out either immediately following RFA or 15 days later. This had acceptably shown a bleeding zone surrounding the central coagulated necrotic area, and after 2 weeks, creation of fibrotic scar tissue was noted. Following Goldberg’s study, Carrara et al. described the feasibility of EUS-guided transluminal RFA of the pancreas on a living pig model. Gaidhane et al. also demonstrated the safety of EUS-guided RFA on the healthy pancreas in five Yucatan pigs showing no mortality and without significant complications.
Therapeutic Advances in Gastroenterology 14

reported. After 70 years from the first curative surgery of a benign pancreatic insulinoma, tumour localizations still remain challenging. According to available literature, surgical therapy is curative in 75% to 98% of patients. As concerns patients with inoperable solid pancreatic lesions or deemed non-surgical candidates, thermal ablations have become increasingly accepted. In addition, RFA prevails the method of choice for biliary-, pancreatic- and peri-luminal lesions.

Testoni et al. recently published a comprehensive literature review on EUS-guided ablation therapies. In addition, the author also elaborated on a novel RFA needle, which was designed with an internal cooling system to reduce the risk of overheating of neighbouring healthy tissue knowing RFA can produce thermal tissue damage due to tissue overheating can be between 60°C and 100°C. Tissue overheating is a result of high frequency, alternating current and frictional heating, resulting in irreversible cellular damage, apoptosis, and coagulative tissue necrosis. The pancreas is a thermo-sensitive organ, and ablation of normal pancreas tissue can lead to an inflammatory reaction causing oedema, cystic transformation and later fibrosis. The first human pilot feasibility and safety study of EUS-guided RFA of the pancreatic lesion was published in 2015 using the Habib™ EUSRFA probe. This was a prospective multi-centre study in which eight patients were enrolled: six with pancreatic cystic neoplasms (four mucinous cystic neoplasms, one intraductal papillary mucinous neoplasm, and one microcystic adenoma) and two with pNETs. All these patients were non-surgical candidates.

Waung et al. reported successful clinical and biochemical response in a sporadic case of 18 mm insulinoma by using the Habib™ RFA probe in a 70-year-old patient, who was not deemed fit for surgical resection due to comorbidities. Eventually, glucose replacement and octreotide therapy were both withdrawn. Lakhtakia et al. similarly assessed the feasibility of the newest RFA probe with an internal cooling system (EUSRA) on symptomatic insulinoma as part of an observational study that included case series of three non-surgical patients. EUSRFA was technically successful in all the patients. Wang et al. reported a 100% technical success rate of EUS–RFA using Habib™ catheter in Stage III pancreatic cancers in a series of three patients. During the first 2 weeks of the follow-up period, a mean reduction in tumour size of 13.49% on further transabdominal US imaging and no complications were observed up to 49-day follow-up period. Pai et al. also demonstrated 100% successful completion of EUS-RFA in eight patients, two of which had neuroendocrine tumours of the pancreatic head. Complete resolution was observed in two out of six patients, and a 50% reduction in size was observed in three out of six patients with the pancreatic cystic lesion. Following EUS-RFA, pNET displayed a change in vascularity and central necrosis within the ablated tissue. No major complication was reported, and only two mild, self-limiting abdominal pain were recorded.

The efficacy of EUS-RFA of neuroendocrine tumours was further reported by Armellini et al. who successfully treated a 20 mm grade 2 endocrine tumour in an asymptomatic 76-year-old patient who had refused surgery. This lesion was completely ablated confirmed by an interval computed tomography (CT) scan, and no major complication was observed up to 1 month of follow-up. Based on the published literature on safety and efficacy, EUS-RFA is deemed safe in cases of locally advanced and metastatic pancreatic cancer. There is an excellent potential in researching the efficacy and safety of EUS-RFA in pancreatic cystic lesions using different endoscopic modalities aiming at effective cytoreductive treatment and, in some cases, a curative treatment. Treatment decisions should still be part of multidisciplinary discussions as this approach had always proven to be efficient in making complex decisions in patients diagnosed with pathological pancreatic lesions.

Imaging techniques. Our systematic review also highlighted an important clinical challenge. In some scenarios, pre-ablation imaging techniques (CT/MRI) did not show pancreatic insulinomas compared to EUS assessment in many reported cases (four out of 34 articles). This indicates that EUS assessment should be considered early to achieve a diagnosis when insulinomas are suspected. An interesting observation in our study is that four authors used the SonoVue contrast agent to demonstrate insulinomas pre- and post-ablation. Contrast-enhanced EUS can also be performed for endoscopic interval assessments.
of these lesions to decide on any further need for ablations.

**Prophylactic stents.** This systematic review also alluded to the use of prophylactic pancreatic and bile duct stent before EUS-EA to prevent subsequent ductal stenosis and acute pancreatitis. Deprez et al. reported a case with insulinoma who received EUS-EA after receiving prophylactic biliary and pancreatic stent with no clinical complication recorded post-procedure; however, there was a mild rise in amylase, which lasted for one day without clinical symptoms. Kandula et al. reported EUS – RFA of insulinoma of a patient who received a prophylactic pancreatic stent 20 days prior ablation; post-procedure, this patient developed mild acute pancreatitis which was treated conservatively. In our opinion, this practice has not been adopted by many practitioners, and this is probably due to non-existing guidelines in prophylactic biliary and pancreatic stenting prior to EUS ablation techniques and further prospective studies required to show efficacy.

**Intra-procedural technical limitations.** The location of insulinomas can be a challenge during ablation, especially if it is close to the mesenteric vessels, the main pancreatic or common bile duct, and superficially located, which may risk a duodenal wall injury. Qin et al. used a reduced dose of infused alcohol to a half or third when the tumour was very close to mesenteric vessels or the main pancreatic duct, as ethanol can cause consequent strictureing of these ducts after ablation. The median size of insulinomas shown in our study was 13 mm x 10 mm. It became apparent that there is no evidence-based consensus on insulinoma size to guide EUS-guided RFA/EA techniques, but based on expert opinion, 2–3 cm lesions can be safely ablated with this technique.

**Comorbidities.** Our results demonstrated that 21 out of 65 patients (32% of all cohort) had multiple co-morbidities, which precluded surgical intervention; however, EUS-guided RFA/E was successful in them.

**Peri-procedural medical and dietetic management.** Our current study reflected that prophylactic antibiotics were used; only four of the 35 included studies documented antibiotic use pre-ablations. Equally poor measures were taken for the prevention of acute pancreatitis, for example, the use of rectal NSAID. This may be explained by the lack of data to support agreed guidelines on EUS-guided ablation techniques.

In the case of inoperable disease or non-surgical candidates, medical treatment has been trialled, typically with Diazoxide which can be ineffective in many cases. In our current review, 8 out of 65 patients had developed side effects before EUS treatment (fluid retention); therefore, Diazoxide was discontinued in these patients. In our cohort, other medical therapy pre-EUS-guided ablations (somatostatin, elozimib, octreotide) proved to be less effective in general.

Medical therapy has its limitations mainly due to a strict diet protocol, including overnight snacks to avoid hypoglycaemic episodes, resulting in weight gain and morbid obesity, and precluding surgical options. Our included cases had shown morbid obesity in six articles. Dietetic support for these patients is essential to manage their condition before EUS-guided RFA/E. The psychological impact cannot be ignored due to the prevalence of depressive disorders, which usually leads to non-compliance with medical therapy. Despite improvement in surgical techniques, especially in tertiary centres, mortality has significantly dropped. However, postoperative morbidity remained as high as 30% in the minimal laparoscopic approach and can reach up to 40–50% in Vázquez Quintana. Therefore, the use of a non-surgical approach (EUS-guided RFA and EUS-EA) should be discussed with patients when offering treatment options for insulinomas.

**Strength and limitations.** Our systematic review’s strength is its rigorous methodology (RFA/E) and the extensive data from all published cases of EUS-guided RFA/E. Our paper has several limitations (a) absence of international consensus around indications of EUS-guided ablation techniques, especially for RFA and EA, as this remains an option for patient’s selection. (b) There were no controlled trials; therefore, we could not make direct comparisons between different treatment methods. (c) We do not have detailed information about several key technical aspects of the RFA generators used for these cases. (d) Other limitations were noted in the lack of reported information about the biochemical assays utilised for the biochemical assessments. This systematic review...
reflected the lack of information on hospital stay duration, BMI, and the follow-up period required to ascertain final treatment outcomes. Finally, all the included articles were case studies and case series, indicating a low level of evidence. Based on Murad et al. quality assessment tool, the EUS-guided RFA/EA techniques were adequately performed in all included cases. On the other hand, 13 out of 34 articles did not contain relevant information about a detailed medical history, medical treatment and follow-up period.

Implications for clinical practice
In conclusion, this systematic review showed that EUS-guided RFA/EA techniques can be considered in the treatment algorithm of pancreatic insulinoma, especially for those patients where surgical intervention is contraindicated. The existing literature provides an overview of the possible complications from EUS-guided ablation and their frequency and severity, which will help discuss the procedure with patients and obtain informed consent. EUS-guided ablations of insulinoma allow patients to avoid the morbidity associated with surgical reductions. The advantage of the EUS-guided RFA/EA technique lies in its easiness, rapidity, low cost, and acceptable morbidities, even in high-risk patients with inadequate surgical conditions. Decisions in managing insulinomas should be part of a multidisciplinary discussion, including endocrinology opinion, surgical opinion, radiologist and an experienced EUS endoscopist.

Implications for research
Our results showed that a prospective (randomised controlled trial) study approach would have been more informative and recommended to be done as part of a multicentre EUS-guided ablation register to include all modalities of EUS-guided ablation techniques.

Conclusion
Our findings support that EUS-guided ablation techniques (RFA/EA) are feasible in treating insulinoma. This technique is safe in expert hands, and adverse events could be anticipated and managed. Therefore, non-surgical intervention with EUS-guided RFA/EA might become the future first-line option in selected cases.

Author contributions

Conceptualisation: Ghassan El-Sayed, Péter J. Hegyi, Bálint Erőss.

Data curation: Ghassan El Sayed, Levente Frim, Jamie Franklin, Raymond McCrudden, Charles Gordon, Safa Al-Shamma, Szabolcs Kiss, Péter Hegyi.

Formal analysis: Levente Frim.

Funding acquisition: Péter Hegyi.

Investigation: Jamie Franklin, Raymond McCrudden, Charles Gordon, Safa Al-Shamma, Péter Hegyi, Ghassan El-Sayed, Bálint Erőss, Péter J. Hegyi.

Methodology: Jamie Franklin, Raymond McCrudden, Charles Gordon, Safa Al-Shamma, Szabolcs Kiss, Péter Hegyi, Bálint Erőss, Péter J. Hegyi.

Supervision: Bálint Erőss, Péter J. Hegyi.

Validation: Péter J. Hegyi.

Writing-original draft: Ghassan El-Sayed, Levente Frim, Jamie Franklin, Raymond McCrudden, Charles Gordon, Safa Al-Shamma, Szabolcs Kiss, Péter Hegyi, Bálint Erőss, Péter J. Hegyi.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work will be funded by the Economic Development and Innovation Operational Programme Grant (GINOP-2.3.2-15-2016-80004 – STAY ALIVE and GINOP-2.3.4-15-2020-00001 Competition Centre for Health Data Analysis, Data Utilisation and Smart Device and Technology Development at the University of Pécs).

ORCID iD
Péter Jenő Hegyi https://orcid.org/0000-0002-6443-0259

Supplemental material
Supplemental material for this article is available online.
References

1. Halldíarnarson TR, Rabe KG and Rubin J. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. *Ann Oncol* 2008; 19: 1727–1733.

2. Kar P, Price P and Sawers S. Insulinomas may present with normoglycemia after prolonged fasting but glucose-stimulated hypoglycemia. *J Clin Endocrinol Metab* 2006; 91: 4733–4736.

3. Whipple AO and Frantz VK. Adenoma of islet cells with hyperinsulinism: a review. *Ann Surg* 1935; 101: 1299–1335.

4. Shin JJ, Gorden P and Libutti SK. Insulinoma: pathophysiology, localization and management. *Future Oncol* 2010; 6: 229–235.

5. Okabayashi T, Shima Y and Sumiyoshi T. Diagnosis and management of insulinoma. *World J Gastroenterol* 2013; 19: 829–837.

6. Burghardt K, Kaemmerer D and Michael A. Successful endoscopic ultrasound-guided ethanol ablation of a symptomatic sporadic insulinoma in a patient with severe comorbidities not suitable for pancreatic surgery. *Diabetes Metabolism* 2018; 44: 84–86.

7. Grant CS. Surgical aspects of hyperinsulinemic hypoglycemia. *Endocrinol Metab Clin North Am* 1999; 28: 533–554.

8. Ho V and Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. *Ann Surg* 2003; 237: 509–514.

9. Fajans SS and Vinik AI. Insulin-producing islet cell tumors. *Endocrinol Metab Clin North Am* 1989; 18: 45–74.

10. Jürgensen C, Schuppan D, Nesper F, et al. EUS-guided alcohol ablation of an insulinoma. *Gastrointest Endosc* 2006; 63: 1059–1062.

11. Armellini E, Crinó SF and Ballarè M. Endoscopic ultrasound-guided ethanol ablation of pancreatic neuroendocrine tumors: a case study and literature review. *World J Gastrointest Endosc* 2016; 8: 192–197.

12. Chaudhary S and Sun S-Y. Endoscopic ultrasound-guided radiofrequency ablation in gastroenterology: new horizons in search. *World J Gastroenterol* 2017; 23: 4892–4896.

13. Barther M, Giovannini M and Lesavre N. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. *Endoscopy* 2019; 51: 836–842.

14. Gan SI, Thompson CC and Lauwers GY. Ethanol lavage of pancreatic cystic lesions: initial pilot study. *Gastrointest Endosc* 2005; 61: 746–752.

15. Omerovič S and Zerem E. Alcohol sclerotherapy in the treatment of symptomatic simple renal cysts. *Bosn J Basic Med Sci* 2008; 8: 337–340.

16. Mittal M, Yip B and Lee JG. Endoscopic ultrasound-guided ethanol ablation for control of local-regional metastatic insulinoma. *Pancreas* 2017; 46: e17–e18.

17. Fu C, Liu N and Deng Q. Successful treatment of gastrointestinal stromal tumor with multiple liver metastases with radiofrequency ablation and imatinib: a case report. *Oncol Lett* 2015; 10: 875–878.

18. Zhang W-Y, Li Z-S and Jin Z-D. Endoscopic ultrasound-guided ethanol ablation therapy for tumors. *World J Gastroenterol* 2013; 19: 3397–3403.

19. Liberati A, Altman DG and Tetzlaff J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ (Clinical Research Ed)* 2009; 339: b2700.

20. Murad MH, Sultan S and Haffar S. Methodological quality and synthesis of case series and case reports. *BMJ Evid Based Med* 2018; 23: 60–63.

21. Altonbary A, Hakim H and Elkashef W. Endoscopic ultrasound-guided ethanol ablation for functioning insulinoma. *Endoscopic Ultrasound* 2017; 6: S45.

22. Bas-Cutrina F, Bargalló D and Gornals JB. Small pancreatic insulinoma: successful endoscopic ultrasound-guided radiofrequency ablation in a single session using a 22-G fine needle. *Dig Endosc* 2017; 29: 636–638.

23. Bor R, Farkas K and Bálint A. Endoscopic ultrasound-guided ethanol ablation: an alternative option for the treatment of pancreatic insulinoma. *Orvosi Hetilap* 2014; 155: 1647–1651.

24. Burghardt K, Kaemmerer D, Michael A, et al. Successful endoscopic ultrasound-guided ethanol ablation of a symptomatic sporadic insulinoma in a patient with severe comorbidities not suitable for pancreatic surgery. *Diabetes Metabolism* 2018; 44: 84–86.

25. Choi JH, Seo DW and Song TJ. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. *Endoscopy* 2018; 50: 1099–1104.

26. Dabkowski K, Gajewska P, Walter K, et al. Successful EUS-guided ethanol ablation of
insulinoma, four-year follow-up. *Endokrynol Pol* 2017; 68: 472–479.

27. de Sousa Lages A, Paiva I, Oliveira P, *et al.* Endoscopic ultrasound-guided ethanol ablation therapy for pancreatic insulinoma: an unusual strategy. *Endocrinol Diabetes Metab Case Rep* 2017; 2017: 160145.

28. De Nucci G, Mandelli ED and Morganti D. Endoscopy ultrasound guided radiofrequency ablation of functioning insulinoma in symptomatic patients unfit for surgery. *Digest Liver Disease* 2018; 50: e159–e160.

29. Deprez PH, Claessens A and Borbach I. Successful endoscopic ultrasound-guided ethanol ablation of a sporadic insulinoma. *Acta Gastro-Enterologica Belgica* 2008; 71: 333–337.

30. Godat S, Lamine F and David G. Video sessions: endoscopic ultrasound (EUS) guided pancreas radiofrequency ablation of a benign insulinoma. *Swiss Medical Weekly* 2018; 148: 12S.

31. Jonica ER and Wagh MS. Endoscopic treatment of symptomatic insulinoma with a new EUS-guided radiofrequency ablation device. *Videogie* 2020; 5: 483–485.

32. Kandula S, Aurangabadker G and Modi V. Management of a difficult case of insulinoma with radiofrequency ablation. *Indian J Endocrinol Metabol* 2019; 23: S46–1S7.

33. Khoo S, Hilmi I and Dhir V. An emerging indication for endoscopic ultrasound: case report of endoscopic ultrasound -guided ablation of a multifocal insulinoma. *Endoscopic Ultrasound* 2017; 6: S25.

34. Kluz M, Staroń R and Krupa Ł. Successful endoscopic ultrasound-guided radiofrequency ablation of a pancreatic insulinoma. *Polish Arch Intern Med* 2020; 130: 145–146.

35. Lee MJ, Jung CH and Jang JE. Successful endoscopic ultrasound-guided ethanol ablation of multiple insulinomas accompanied with multiple endocrine neoplasia type 1. *Intern Med J* 2013; 43: 948–950.

36. Levy MJ, Thompson GB and Topazian MD. US-guided ethanol ablation of insulinomas: a new treatment option. *Gastrointest Endosc* 2012; 75: 200–206.

37. Luo YP, Li J and Yang AM. Ga-68-Exendin-4PET/CT in evaluation of endoscopic ultrasound-guided ethanol ablation of an insulinoma. *Clin Nucl Med* 2017; 42: 310–311.

38. Mosquera-Klinger G and Carvajal JJ. Endoscopic ultrasound-guided ethanol ablation for the management of a symptomatic pancreatic insulinoma. *Rev Esp Enferm Dig* 2020; 113: 48–51.

39. Nelson K, Lakha A and Malafa M. Symptomatic pancreatic insulinoma successfully treated with alcohol ablation. *Am J Gastroenterol* 2014; 109: S456.

40. Oleinikov K, Dancour A and Epshtein J. Endoscopic ultrasound-guided radiofrequency ablation: a new therapeutic approach for pancreatic neuroendocrine tumors. *J Clin Endocrinol Metabol* 2019; 104: 2637–2647.

41. Paik WH, Seo DW and Dhir V. Safety and efficacy of EUS-guided ethanol ablation for treating small solid pancreatic neoplasm. *Medicine (Baltimore)* 2016; 95: e2538.

42. Park DH, Choi JH and Oh D. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. *Clin Endosc* 2015; 48: 158–164.

43. Qin S, Jiang H and Luo W. Efficacy of EUS-guided ethanol injection in the treatment of benign and symptomatic insulinomas. *Gastroenterology* 2016; 150: S510.

44. Sharma NR, Sharma A and Perelman A. Spare the Whipple: novel endoscopic radiofrequency ablation treatment for insulin secreting tumors. *Am J Gastroenterol* 2017; 112: S1133.

45. Schnack C, Hansen C and Nielsen HO. Successfull endoscopic ultrasound-guided alcoholic ablation of insulinoma. *Neuroendocrinology* 2011; 94: 43.

46. Silva F, Colaiacovo R and Araki O. Endoscopic ultrasound-guided fine needle injection of alcohol for ablation of an insulinoma: a well documented successful procedure. *Endoscopy* 2019; 51: E57–E58.

47. Trevino J, Calloway J and Eloubeidi M. EUS-guided ablation of pancreatic insulinomas. *Gastrointest Endosc* 2011; 73: AB110.

48. Trikudanathan G, Mallery SJ and Amateau SK. Successful endoscopic ultrasound-guided alcohol ablation of sporadic insulinoma using three-dimensional targeting (with video). *Clin Endosc* 2016; 49: 399–401.

49. Vleggaar FP, de Vaate EAB and Valk GD. Endoscopic ultrasound-guided ethanol ablation of a symptomatic sporadic insulinoma. *Endoscopy* 2011; 43: E328–E329.

50. Waung JA, Todd JF and Keane MG. Successful management of a sporadic pancreatic insulinoma by endoscopic ultrasound-guided radiofrequency ablation.
51. Zalewska E, Klosowski P and Dubowik M. Endoscopic ultrasound-guided ethanol ablation of insulinoma. *Endokrynologia Polska* 2020; 71: 585–586.

52. Zarug KR, Ronshaugen N and Mehendiratta V. EUS-guided ethanol ablation as a treatment option for insulinoma. *Endocrine Reviews* 2015; 36, https://endo.confex.com/endo/2015endo/webprogram/Paper20051.html

53. Lakhtakia S, Memon SFF and Medarapalem JB. 99 sustained clinical response with eus guided rfa of pancreatic insulinoma. *Gastrointest Endosc* 2020; 91: AB14.

54. Goldberg SN, Mallery S and Gazelle GS. EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. *Gastrointest Endosc* 1999; 50: 392–401.

55. Kim HJ, Seo DW and Hassanuddin A. EUS-guided radiofrequency ablation of the porcine pancreas. *Gastrointest Endosc* 2012; 76: 1039–1043.

56. Matthes K, Mino-Kenudson M and Sahani DV. Concentration-dependent ablation of pancreatic tissue by EUS-guided ethanol injection. *Gastrointest Endosc* 2007; 65: 272–277.

57. Luz LP, Al-Haddad MA and DeWitt JA. EUS-guided celiac plexus interventions in pancreatic cancer pain: an update and controversies for the endosonographer. *Endosc Ultrasound* 2014; 3: 213–220.

58. Lee KH and Lee JK. Interventional endoscopic ultrasoundography: present and future. *Clin Endosc* 2011; 44: 6–12.

59. Limmer S, Huppert PE and Juette V. Radiofrequency ablation of solitary pancreatic insulinoma in a patient with episodes of severe hypoglycemia. *Eur J Gastroenterol Hepatol* 2009; 21: 1097–1101.

60. Carrara S, Arcidiacono PG and Albarello L. Endoscopic ultrasound-guided application of a new hybrid cryotherm probe in porcine pancreas: a preliminary study. *Endoscopy* 2008; 40: 321–326.

61. Signoretti M, Valente R and Repici A. Endoscopy-guided ablation of pancreatic lesions: technical possibilities and clinical outlook. *World J Gastrointest Endosc* 2017; 9: 41–54.

62. Gaidhane M, Smith I and Ellen K. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) of the pancreas in a porcine model. *Gastroenterol Res Pract* 2012; 2012: 431451.

63. Tucker ON, Cotty PL and Conlon KC. The management of insulinoma. *Br J Surg* 2006; 93: 264–275.

64. Finlayson E and Clark OH. Surgical treatment of insulinomas. *Surg Clinics North Am* 2004; 84: 775–785.

65. Larghi A, Rizzatti G, Rimbaš M, et al. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: who should we treat. *Endosc Ultrasound* 2019; 8: 220–226.

66. Lakhtakia S. Therapy of pancreatic neuroendocrine tumors: fine needle intervention including ethanol and radiofrequency ablation. *Clin Endosc* 2017; 50: 546–551.

67. Decadt B and Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. *Lancet Oncol* 2004; 5: 550–560.

68. Testoni SGG, Healey AJ and Dietrich CF. Systematic review of endoscopy ultrasound-guided thermal ablation treatment for pancreatic cancer. *Endosc Ultrasound* 2020; 9: 83–100.

69. Paiella S, Salvia R and Ramera M. Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation): a review. *Gastroenterol Res Pract* 2016; 2016: 4508376.

70. Chu KF and Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. *Nat Rev Cancer* 2014; 14: 199–208.

71. Egorov AV, Vasiliev IA and Musayev GH. The role of microwave ablation in management of functioning pancreatic neuroendocrine tumors. *Gland Surg* 2019; 8: 766–772.

72. Öberg K. Management of functional neuroendocrine tumors of the pancreas. *Gland Surg* 2018; 7: 20–27.

73. Lakhtakia S, Ramchandani M and Galasso D. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). *Gastrointest Endosc* 2016; 83: 234–239.

74. Wang D, Jin Z and Lei W. Mo1524 endoscopic ultrasound guided radiofrequency ablation for the treatment of advanced pancreatic carcinoma. *Gastrointest Endosc* 2013; 77: AB414.

75. Pai M, Habib N and Senturk H. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. *World J Gastrointest Surg* 2015; 7: 52–59.

76. Armellini E, Crinò SF and Ballarè M. Endoscopic ultrasound-guided radiofrequency...
ablation of a pancreatic neuroendocrine tumor. *Endoscopy* 2015; 47: 600–601.

77. Rossi S, Viera FT and Ghittoni G. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. *Pancreas* 2014; 43: 938–945.

78. Shirota T, Nagakawa Y and Sahara Y. Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach. *Gland Surg* 2018; 7: 12–19.

79. Al-Kurd A, Chapchay K and Grozinsky-Glasberg S. Laparoscopic resection of pancreatic neuroendocrine tumors. *World J Gastroenterol* 2014; 20: 4908–4916.

80. Vázquez Quintana E. The surgical management of insulinoma. *Boletin de la Asociacion Medica de Puerto Rico* 2004; 96: 33–38.